To compare the proportion of secondary loss of response to adalimumab and infliximab during maintenance treatment of ulcerative colitis (UC) after primary response to induction therapy.
The efficacy of anti-tumor necrosis factor-α (TNF-α) therapy used to maintain response in patients with UC after primary response to induction therapy wanes with time, resulting in secondary loss of response.
A retrospective cohort study evaluating anti-TNF-naive UC outpatients who were primary responders to adalimumab and infliximab induction therapy and who advanced onto a maintenance regimen with the respective anti-TNF agent from 2003 to 2013 was conducted. The primary outcome was the proportion of patients in each treatment group that had secondary loss of response. The secondary outcome was time to secondary loss of response, analyzed by the Kaplan-Meier method analysis.
A total of 102 UC primary anti-TNF responders met inclusion criteria. Thirty-six patients (35.3%) were treated with adalimumab and 66 patients (64.7%) with infliximab. Mean follow-up was 139.0 weeks for adalimumab and 158.8 weeks for infliximab. A total of 21/36 (58.3%) adalimumab-treated patients and 39/66 (59.1%) infliximab-treated patients experienced a secondary loss of response during maintenance therapy. Mean time to secondary loss of response was similar for adalimumab (55.8 wk) and infliximab (59.4 wk) (P=0.82). Sex, extent of colitis, previous or concomitant azathioprine, and concurrent corticosteroids with anti-TNF induction were not associated with increased risk of secondary loss of response.
In this real-life cohort of anti-TNF-naive primary responders with UC, the proportion of secondary loss of response and the time to secondary loss of response are similar for adalimumab and infliximab.
Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.jcge.com.
C.M., V.H., and D.K.F. are co-first authors.
Supported in part by the Alberta Innovates Health Solutions, Alberta Inflammatory Bowel Disease Consortium, the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), and the Cecile Mactaggart Summer Studentship Award (DKF).
R.N.F. is acting as the article guarantor and contributed to study design, data collection, data analysis, manuscript drafting, and editing. C.M., V.H., and D.K.F. contributed to data collection, data analysis, manuscript drafting, and editing. K.I.K., L.A.D., and B.P.H. contributed to manuscript editing. All authors have approved the final version of the manuscript, including the authorship list.
R.N.F., K.I.K., B.P.H., and L.A.D. have served as a speaker and consultant for Abbvie Canada Inc. and Janssen Canada Inc. The remaining authors declare that they have nothing to disclose.
Reprints: Richard N. Fedorak, MD, FRCPC, Division of Gastroenterology, University of Alberta, 2-14 A Zeidler Building, Edmonton, AB, Canada T6G 2X8 (e-mail: email@example.com).
Received April 21, 2014
Accepted October 5, 2014